Alendronate (Fosamax, Fosamax Plus D, and generic), the first bisphosphonate approved by the Food and Drug Administration for the treatment and prevention of osteoporosis, came on the market in 1995 and proved to be a moneymaker, bringing in nearly $3.2 billion in 2005.